dutasteride capsule / Generic mfg. - LARVOL DELTA

Androgenetic alopecia drugs and male infertility: Evidence from pharmacovigilance and testicular transcriptomics. (PubMed, PLoS One) - "This study systematically evaluated associations between AGA drugs and male infertility using real-world pharmacovigilance data and integrated bioinformatic analyses. The HIF1A-related transcriptomic findings provide a hypothesis-generating biological context for male infertility but do not establish a shared or drug-specific mechanism linking the three medications to infertility. The pharmacovigilance findings indicate reporting signals rather than incidence or causality."

Adverse events • Journal • Alopecia • Immunology • Infertility • Sexual Disorders • FGF • HIF1A

Oral medications for hair loss in the elderly (EADV 2026) - "This includes low-dose oral minoxidil, finasteride, dutasteride, spironolactone, hydroxychloroquine and JAK inhibitors. Learning Objectives After this presentation, participants should be able to: Select suitable oral treatments for androgenetic alopecia, frontal fibrosing alopecia and alopecia areata.Assess cardiovascular, renal, thrombotic, infectious and oncological risks before treatment. Apply recent recommendations on low-dose oral minoxidil and JAK inhibitors."

Clinical • Alopecia • Cardiovascular • Fibrosis • Immunology • Infectious Disease • Lichen Planus • Nephrology • Renal Disease • Thrombosis

The Impact of Common Medications on Male Fertility: An Updated Systematic Review. (PubMed, Andrology) - "In this updated review, evidence-based recommendations for clinical management and for possible fertility preservation or contraception in men of reproductive age receiving common acute or chronic medical treatment are provided, with the goal of making these data more readily available to medical staff."

Journal • Review • Infertility

Telmisartan Repurposing Targets Novel Biomarkers for Precision Colorectal Cancer Therapy. (PubMed, Pharmaceutics) - "Based on in silico predicted deleterious mutations and subsequent molecular docking-based virtual screening, Telmisartan, Dutasteride and Venetoclax were prioritized. Conclucions: Our findings conclude that Telmisartan is a promising candidate for drug repurposing for CRC treatment and capable of modulating selected novel biomarkers CLUH and SLC11A2. However, further multi-omics-based confirmatory studies and pre-clinical validation studies are needed in the future to confirm the long-term efficacy of this repositioning strategy."

Biomarker • Journal • Colorectal Cancer • Oncology • Solid Tumor • SLC11A2

Hair regrowth in female androgenetic alopecia combining microneedling-assisted delivery of minoxidil and dutasteride with topical minoxidil and oral spironolactone (EADV 2026) - No abstract available

Alopecia • Immunology

Intralesional Dutasteride for Androgenetic Alopecia: A Systematic Review and Meta-Analysis Revealing High Response Rates with Minimal Systemic Risk (EADV 2026) - No abstract available

Retrospective data • Review • Alopecia • Immunology

Regenerative Versus Antiandrogen Therapy in Androgenetic Alopecia: Nanofat Compared with Intradermal Dutasteride (EADV 2026) - No abstract available

Alopecia • Immunology

A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia (clinicaltrials.gov) - P3 | N=288 | Recruiting | Sponsor: Chong Kun Dang Pharmaceutical | Trial completion date: Sep 2027 ➔ Jun 2028 | Trial primary completion date: Dec 2026 ➔ Sep 2027 | Not yet recruiting ➔ Recruiting

Enrollment open • Trial completion date • Trial primary completion date • Alopecia • Dermatology • Immunology

Black Race Predicts Poor Compliance and Higher Prostate Cancer Risk in a Multinational Repeat Biopsy Cohort: Secondary Analysis From the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) Clinical Trial. (PubMed, Prostate) - "Among patients with a negative prestudy biopsy on a phase 3 trial, black patients had lower compliance with study-mandated biopsy but were 2.44 times more likely to have GG2 + PC on the 2-year biopsy versus white patients. These data extend population and initial biopsy data to first repeat biopsy, strongly supporting that black race is linked with aggressive PC. Given differential biopsy compliance may be greater in the real-world, these data suggest population data may underestimate true racial disparities in PC risk and aggressiveness."

Compliance • Journal • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Modern treatment of androgenetic alopecia (PubMed, Orv Hetil) - "The management of androgenetic alopecia is a rapidly evolving field requiring personalized therapeutic decisions. In clinical practice, a personalized combined treatment strategy and regular follow-up are of paramount importance. Orv Hetil. 2026; 167(35): 1385-1393."

Journal • Review • Alopecia • Immunology

Hair Growth-Supporting and Follicle-Protective Potential of a Botanical-Based Supplement Ingredient: In Vitro, Ex Vivo, and Molecular Docking Studies. (PubMed, Biomolecules) - "Molecular docking (AutoDock Vina) of the main Elissara bioactives (oleuropein, hydroxytyrosol, verbascoside, carnosic acid, carnosol, and quercetin) identified SRD5A2 as a favorable predicted target, with individual binding energies ranging from -8.70 to -9.73 kcal/mol, approaching finasteride/dutasteride reference values. Together, these findings support the potential of Elissara as a promising nutricosmetic ingredient for supporting follicular resilience through multiple follicle-relevant pathways. Clinical studies assessing hair growth outcomes are needed to determine whether these preclinical findings translate into measurable benefits."

IO biomarker • Journal • Preclinical • BCL2 • IGF1 • SRD5A2

THE ASSOCIATION BETWEEN 5-ALPHA REDUCTASE INHIBITORS AND PROSTATE CANCER MORTALITY (AUA 2024) - "Funded by Canadian Urological Association Scholarship Fund INTRODUCTION AND OBJECTIVE: 5-alpha-reductase-inhibitors (5-ARIs), finasteride and dutasteride, are approved for treating benign prostatic hyperplasia (BPH), and reduce prostate cancer risk by 25%...Cox proportional hazard models with inverse probability treatment weights (IPTW) were used adjusting for prognostic covariates (age, income quintile, rurality, stage, morphology type, laterality, PSA, total Gleason score, total number of positive cores, maximum percent core, primary treatment, prior statin, post-treatment statin, prior metformin, post-treatment metformin)... In our large population-based study, pre-diagnostic 5-ARI use was not associated with PCa-specific mortality or all-cause mortality. These data offer reassuring safety data for patients using 5-ARI for both benign and chemopreventive reasons."

Benign Prostatic Hyperplasia • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • Urology

The Association of 5-α Reductase Inhibitors for Benign Prostatic Hyperplasia with Development of Male Breast Disease and Erectile Dysfunction: A Retrospective Cohort Study of TriNetX Database. (PubMed, Urology) - "In this multi-institutional retrospective cohort study, we did not find an increased risk of MBC associated with 5ARI use."

Journal • Retrospective data • Benign Prostatic Hyperplasia • Breast Cancer • Erectile Dysfunction • Male Breast Cancer • Oncology • Solid Tumor

SAFETY OF TAMSULOSIN ALONE OR IN COMBINATION WITH 5Α-REDUCTASE INHIBITORS ON LIPID PROFILE, RENAL FUNCTION, AND LIVER PARAMETERS. (PubMed, Georgian Med News) - "Tamsulosin administered alone or in combination with finasteride or dutasteride for more than three months demonstrated non-significant differences in the measured biochemical parameters among the studied groups represented by no adverse effects on lipid metabolism, renal function, liver enzymes, or bilirubin homeostasis. These findings support the safe use of these therapeutic regimens in elderly BPH patients, including those with underlying metabolic or organ function concerns. Further prospective longitudinal studies with larger sample sizes are warranted to confirm these observations."

Journal • Benign Prostatic Hyperplasia • Metabolic Disorders

Ready-to-use, spheronized drug particles-embedded iron(III)-reinforced carboxymethyl cellulose hydrogels as novel long-acting injectable platform with reduced local inflammation. (PubMed, Int J Pharm) - "Dutasteride (DTS), a lipophilic 5α-reductase inhibitor prescribed for benign prostatic hyperplasia, was selected as a model compound...Furthermore, Fe3⁺-CMC HG elicited substantially reduced local inflammation at the injection site compared with native CMC HG and ISFI. Collectively, these findings support Fe3⁺-CMC HG as an effective and biocompatible LAI platform for hydrophobic drugs such as DTS."

Journal • Benign Prostatic Hyperplasia • Inflammation

The Impact of Dutasteride Treatment on Subsequent Multiparametric Prostate Magnetic Resonance Imaging Sequences and PI-RADS Score in Patients With PI-RADS 3 Lesions in the Transitional Zone. (PubMed, Int J Urol) - "In benign TZ PI-RADS 3 lesions, dutasteride did not affect PI-RADS up-/downgrading of persistent lesions but was independently associated with a higher rate of complete lesion disappearance, a greater reduction in lesion size, and a greater increase in lesion ADC; the T2WI ratio change did not differ between groups. Because these changes can make benign lesions appear less conspicuous, dutasteride use should be conveyed to the radiologist interpreting follow-up mp-MRI."

Journal • Retrospective data • Oncology • Prostate Cancer

Steroid 5α-reductases in the brain: From neurosteroidogenesis to therapeutic implications. (PubMed, Front Neuroendocrinol) - "These advances may provide a framework for understanding the complex neurobehavioral profile of 5αR inhibitors such as finasteride and dutasteride. In this comprehensive review, we synthesize pharmacological, genetic, and behavioral evidence on the distinct contributions of 5αR1 and 5αR2 to steroid signaling across stress, sex, and development. Finally, we outline several open questions in the biology of 5αRs, the resolution of which will be essential to advancing toward mechanistically precise and clinically actionable interventions."

Journal • Review • CNS Disorders • Depression • Mood Disorders • Psychiatry • Sexual Disorders • Tic Disorders • Tourette Syndrome • SRD5A3

Efficacy and safety of oral finasteride versus dutasteride in moderate-to-severe androgenetic alopecia in males based on trichoscopic and laboratory findings: a clinical comparison in Iran. (PubMed, J Dermatolog Treat) - "Finasteride and dutasteride improved hair density with similar safety. Dutasteride caused stronger PSA reduction, suggesting more potent 5-alpha-reductase inhibition."

Clinical • Journal • Alopecia • Erectile Dysfunction • Immunology

Additive Effects of Platelet-Rich Plasma and Systemic Therapies in Androgenetic Alopecia: A Retrospective Study. (PubMed, Skin Appendage Disord) - "Established treatments for androgenetic alopecia (AGA) include low-dose oral minoxidil (LDOM), spironolactone, finasteride, dutasteride, and platelet-rich plasma (PRP). Combination therapy showed numerically higher but statistically nonsignificant improvements without increased adverse effects. These findings support further prospective studies to optimize combination regimens and patient selection by AGA severity."

Journal • Retrospective data • Alopecia • Immunology

Hypoactive Sexual Desire Disorder in Menopausal Women: Dermatologic Implications of Antiandrogen and Testosterone Therapy. (PubMed, J Am Acad Dermatol) - No abstract available

Journal • Alopecia • Sexual Disorders

Sexual dysfunction associated with 5α-reductase inhibitors in the treatment of androgenetic alopecia: a systematic review. (PubMed, Front Med (Lausanne)) - "Key search terms included "5α-reductase inhibitors" or "5-ARIs" or "finasteride" or "dutasteride" AND "side effects" or "sexual side effects" or "sexual" or "sexual dysfunction" AND "androgenetic alopecia" or "male pattern hair loss" or "female pattern hair loss." Data synthesis included findings from 41 studies, comprising 33 primary-evidence studies in AGA/MPHL/FPHL populations and 8 supporting-evidence studies providing pharmacokinetic, mixed-indication, or comparative context...Overall, clinicians should counsel patients that most sexual side effects reported in controlled AGA studies are infrequent, mild, and reversible, but individual susceptibility varies. Shared decision-making, careful monitoring of sexual function, and further high-quality long-term studies-using standardized definitions of sexual dysfunction and persistence-are needed to quantify risks..."

Journal • Review • Alopecia • Benign Prostatic Hyperplasia • Erectile Dysfunction • Immunology • Sexual Disorders

Assessing the impact of prostate cancer prevention and detection initiatives. (PubMed, Int J Palliat Nurs) - "(2) Chemoprevention-finasteride and dutasteride cut incidence of prostrate cancer by ≈25 %, however, there are side effects which must be managed. Integrating accurate diagnostics, culturally sensitive education, low-barrier outreach and lifestyle counselling offers the strongest pathway to equitable, sustainable prostate cancer control. Future studies should evaluate cost effectiveness and long-term adherence in diverse settings."

Journal • Review • Genetic Disorders • Genito-urinary Cancer • Obesity • Oncology • Prostate Cancer • Solid Tumor • PCA3

Drug combination choices of 5α-reductase inhibitors and α-blockers in patients with benign prostatic hyperplasia: a study based on the FAERS database. (PubMed, Front Med (Lausanne)) - "Notably, the combination of tamsulosin and dutasteride significantly prolonged the time to resistance to dutasteride in BPH patients...The results provide meaningful insights into optimizing drug selection in BPH treatment. We recommend close monitoring of relevant safety parameters when implementing combination therapies."

Journal • Benign Prostatic Hyperplasia • Hypotension • Renal Disease • Sexual Disorders

Dutasteride-loaded nanostructured lipid carrier for androgenic alopecia treatment - An in vivo study. (PubMed, Bioimpacts) - "NLCs may have facilitated the follicular delivery of the anti-hair loss drugs. Since the NLCs have potential for accumulation in the hair follicles, the interval of formulation usage may have been increased to more than once a week which was of great interest to the practitioners aiming at developing more efficient formulations for androgenetic alopecia."

Journal • Preclinical • Alopecia • Immunology

Real-world efficacy and tolerability of oral dutasteride combined with oral minoxidil for male androgenetic alopecia: a retrospective cohort study (BAD 2026) - "Adverse effects were uncommon, with a minority reporting low mood (6.3%) or decreased libido (4.2%). In men with AGA, realworld oral dutasteride–minoxidil was well tolerated and associated with near-universal stabilization by month 6 and progressive improvement, including 71.4% responders by month 9."

Real-world • Real-world effectiveness • Real-world evidence • Retrospective data • Alopecia • Immunology